Azvudine Basic information
|
Product Name: |
Azvudine |
|
Synonyms: |
4'-C-azido-2'-deoxy-2'-fluoro-beta-D-arabinocytidine; 2(1H)-PyriMidinone,4-aMino-1-(4-C-azido-2-deoxy-2-fluoro-b-D-arabinofuranosyl)-; 4-Amino-1-(4-C-azido-2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-2(1H)-pyrimidinone; RO0622; 4'-C-Azido-2'-deoxy-2'-fluoro-b-D-arabinocytidine; 4'-Azido-2'-deoxy-2'-fluoroaracytidine; Azvudine; Azvudine(RO0622) |
|
CAS: |
1011529-10-4 |
|
MF: |
C9H11FN6O4 |
|
MW: |
286.2198432 |
|
EINECS: |
/ |
Azvudine Indications
|
Indications |
Inhibit reverse transcription and replication of HIV in vivo; COVID-19 |
In February 2020, Azvudine was found to be able to resist the new coronavirus, and it was approved for Phase III clinical trials in April 2020. Now that Phase III clinical trials are over.
The clinical effect of azvudine is as follows. Generally, the nucleic acid turns negative after 3-4 days of oral administration. About 300 to 400 cases were done in the second phase of clinical trials, and more than 800 cases were done in the third phase of clinical trials. From the results of the Phase II clinical and some Phase III clinical trials, we can see that the nucleic acid turns negative in about 3-4 days. The medication can be stopped after 6-7 days, and usually discharged within 9 days.
Hot Tags: azvudine cas no.1011529-10-4, China, manufacturers, suppliers, factory, custom, wholesale, CAS NO 25561 30 2, CAS NO 100 51 6, Benzyl alcohol, CAS NO 540 88 5, BSA, CAS NO 87 41 2
